Celularity Case Studies

BIOVANCE®

Optimizing outcomes post-op for pelvic organ prolapse

ANUJ K. CHOPRA, MD – DANVILLE, PA

"I used BIOVANCE to enhance the healing process and to provide a barrier for the mesh"

PRESENTATION

Background:	This is a 78-year-old female patient that was referred for recurrent urinary tract infections and stress incontinence.
Initial Treatment:	• Patient was examined thoroughly, and the post void residual (PVR) volume was noted.
Findings/Studies:	• PVR 120cc • Cystocele noted • Urethral hypermobility • Prolapse noted
Cause:	Bladder protruding into the vagina was noted to be the cause of the pelvic organ prolapse.
Location:	Vagina

TREATMENT STRATEGY

- Patient to be taken to OR for a cystocele repair
- Placement of a pubovaginal sling and mesh
- Apply BIOVANCE® to provide a barrier

Patient Background

Female | Age: 78

Hysterectomy
Diabetes mellitus
Recurrent urinary tract infection
Stress incontinence
Atrophic vaginitis



Evidence of a cystocele



Vaginal dissection



Placement of pubovaginal sling and mesh for cystocele repair



BIOVANCE application

POST-OP

- Patient was discharged and follow-up visits to monitor the progression of healing at surgical site



Complete repair

POST-OP ADDITIONAL COMMENTS

- Using BIOVANCE provided a barrier over the mesh without any complications intra-operatively
- Post operatively it was also noted that there were no complications to the surgical site
- After 3 months of follow-up visits, patient continued to be continent and has adequate support with no evidence of mesh protrusion

AFTER TREATMENT OUTCOMES

- No evidence of mesh protrusion

INDICATIONS FOR USE

BIOVANCE is an allograft intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. As a barrier membrane, BIOVANCE is intended to protect the underlying tissue and preserve tissue plane boundaries with minimized adhesion or fibrotic scarring. Indications include, but are not limited to, surgical covering, wrap or barrier, application to partial- and full-thickness, acute and chronic wounds (such as, traumatic and complex wounds, burns, surgical and Mohs surgery sites; and diabetic, venous, arterial, pressure and other ulcers), including wounds with exposed tendon, muscle, bone or other vital structures.

CONTRAINDICATIONS, WARNINGS, AND PRECAUTIONS

BIOVANCE is contraindicated in patients with a known hyper-sensitivity to BIOVANCE. If a patient has an adverse reaction related to the use of BIOVANCE, immediately discontinue its use. BIOVANCE should not be used on clinically infected wounds.

The pouch contents are sterile if the pouch is unopened and undamaged. Do not use if package seal is broken. Discard material if mishandling has caused possible damage or contamination. Do not resterilize.

BIOVANCE must be used prior to the expiration date on the product pouch. BIOVANCE should not be used together with a collagenase product on the wound.

Please refer to the BIOVANCE Package Insert for complete product information.

For product information, product complaints, or adverse reaction reporting, call 1-844-963-2273.

For more information, please contact Celularity at 1-844-963-2273 or visit www.biovance.net

celularity